Thinking of joining a study?

Register your interest

Become a volunteer?

NCT03221257 | COMPLETED | Scleroderma, Systemic

Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate
Sponsor:

Michael Roth

Information provided by (Responsible Party):

Michael Roth

Brief Summary:

A Phase II multi-center, double-blind, parallel group, randomized and placebo-controlled clinical trial addressing the treatment of patients with active and symptomatic Scleroderma-related interstitial lung disease (SSc-ILD).

Condition or disease

Scleroderma, Systemic

Interstitial Lung Disease

Intervention/treatment

Pirfenidone (PFD)

Placebo (Plac)

Mycophenolate Mofetil (MMF)

Phase

PHASE2

Detailed Description:

A Phase II multi-center, double-blind, parallel group, randomized and placebo-controlled clinical trial addressing the treatment of patients with active and symptomatic Scleroderma-related interstitial lung disease (SSc-ILD). Patients who are either treatment naive or only recently started treatment (\</= 6 months of prior treatment) will be randomized in a 1:1 assignment to receive either oral mycophenolate mofetil (MMF) and a placebo (Plac) or a combination of oral MMF and oral pirfenidone (PFD), with both regimens administered for 18 months. The primary hypothesis is that the rapid onset and anti-fibrotic effects of PFD, which have been observed in the treatment of Idiopathic Pulmonary Fibrosis (IPF), will complement the delayed antiinflammatory and immunosuppressive effects of MMF, to produce a significantly more rapid and/or greater improvement in lung function over time than occurs in patients receiving control therapy with MMF and Plac.

Study Type : INTERVENTIONAL
Estimated Enrollment : 51 participants
Masking : TRIPLE
Primary Purpose : TREATMENT
Official Title : Scleroderma Lung Study III (SLS III): Combining the Anti-fibrotic Effects of Pirfenidone (PFD) With Mycophenolate (MMF) for Treating Scleroderma-related Interstitial Lung Disease
Actual Study Start Date : 2017-11-28
Estimated Primary Completion Date : 2022-03-23
Estimated Study Completion Date : 2022-06-13

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • 1. Age ≥18 yrs
  • 2. Scleroderma as determined by the 2013 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria.
  • 3. Grade ≥2 on the Magnitude of Task component of the Mahler Modified Dyspnea Index
  • 4. FVC-% of ≤85% at screening
  • 5. Onset of the first non-Raynaud manifestation of SSc within the prior 84 months.
  • 6. Presence of any ground-glass opacification (GGO) on thoracic high-resolution computed tomography (HRCT)
  • 7. Repeat FVC-% at the baseline visit within 10% of the FVC-% value measured at screening. If these criteria are not met, a repeat FVC-% may be obtained within 7 days and the subject may qualify for randomization if the repeat FVC-% agrees within 10% of the FVC-% obtained at screening.
Exclusion Criteria
  • 1. Disease features supporting the primary diagnosis of another connective tissue disease such as rheumatoid arthritis, systemic lupus erythematosus or mixed connective tissue disease (Features consistent with a secondary Sjogren syndrome or scleroderma-associated myopathy will be allowed).
  • 2. FVC-% of \<45% at either screening or baseline.
  • 3. Forced Expiratory Volume in the first second (FEV1)/Forced Vital Capacity (FVC) ratio \<0.65 at either screening or baseline.
  • 4. Diffusing capacity of the lung for carbon monoxide adjusted for hemoglobin, expressed as a percentage of the normal predicted value (DLCOHb-%) of \<30% at screening or \<25% at baseline.
  • a) All participants with a DLCOHb-% between 30 to 40% must have pulmonary artery pressures documented by either echocardiogram, right heart catheterization or magnetic resonance imaging in order to be considered for inclusion.
  • 5. Diagnosis of clinically significant resting pulmonary hypertension requiring treatment or mild pulmonary hypertension requiring treatment with more than one oral medication as ascertained prior to study evaluation or as part of a standard of care clinical assessment performed outside of the study protocol.
  • 6. Evidence of uncontrolled congestive heart failure, unstable ischemic heart disease, history of complicated pulmonary embolism impacting on heart or lung function, or unstable cardiac arrhythmia requiring chronic anticoagulation.
  • 7. Clinically significant abnormalities on HRCT not attributable to SSc
  • 8. Hematologic abnormality at screening including
    • 1. Leukopenia (white blood cells \[WBC\] \<4.0x10\^3/µl).
    • 2. Thrombocytopenia (platelet count \<120.0x10\^3/µl).
    • 3. Clinically significant anemia \[Hemoglobin (Hgb) \<10.0 g/dl\].
    • Participants with an identified and correctable etiology may be eligible if repeat testing within the maximal 90-day screening period meets all criteria.
    • 9. A diagnosis of chronic liver disease or abnormal baseline liver function test (LFTs) or total bilirubin that are \>2.0 x upper normal limit
    • 10. Serum creatinine \>2.0mg/dl
    • 11. History of recurrent aspiration, uncontrolled heartburn, or gastroesophageal reflux disease (GERD) with a reflux scale score of \>1.00 as determined by a UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Scale (UCLA SCTC GIT), Version 2.0.
    • Participants with uncontrolled heartburn or GERD that is amenable to medical management may be eligible if repeat testing within the maximal 90-day screening period meets this criteria.
    • 12. Known achalasia, esophageal stricture or esophageal dysfunction sufficient to limit the ability to swallow medication.
    • 13. Pregnancy (as documented by blood test) and/or breast feeding
    • 14. If of child bearing potential (a female participant \< 55 years of age who has not been postmenopausal for ≥ 5 years or who has not had a bilateral salpingectomy, hysterectomy and/or oophorectomy), failure to employ two reliable means of contraception which may include surgical sterilization, barrier methods, spermicides, intrauterine devices, and/or hormonal contraception, unless the participant chooses abstinence (to avoid heterosexual intercourse completely). If a subject chooses abstinence, then a second reliable means of contraception is not needed.
    • 15. Prior use of potential disease modifying antirheumatic drugs (DMARDs) according to the following exposure rules
      • 1. Use of oral cyclophosphamide (CYC), MMF, azathioprine or other oral or short half-life DMARDs (as detailed in Protocol Section 7.5.1a) for more than 6 months in the past year as determined at the time of the initial screening visit.
      • 2. Treatment with more than three intravenous doses of CYC, one treatment course of Rituximab or other intravenous or injectable DMARDs (as detailed in Protocol Section 7.5.1b) in the past year.
      • 3. More distant history of treatment with a DMARD is allowed as long as the patient has a new diagnosis/new episode of active SSc-ILD since stopping that treatment and meets the criteria noted in 15a or 15b.
      • 16. Use of CYC, MMF, azathioprine, Rituximab or other DMARD (as defined in Protocol Section 7.5.1a\&b) in the 30 days prior to their baseline visit unless the patient is on MMF and the responsible physician indicates that continued use is in the best clinical interest of the patient.
      • 17. Active infection (lung, ulcers or elsewhere) whose management would be compromised by immunosuppression.
      • 18. Other serious concomitant medical illness (e.g., active malignancy within the past 5 years other than surgically-removed local skin cancer such as a basal cell carcinoma), chronic debilitating illness (other than SSc), unreliability or drug abuse that might compromise the patient's participation in the trial.
      • 19. Current use, or use within the 30 days prior to their baseline visit, of prednisone (or equivalent) in doses \>10 mg/day.
      • 20. Smoking of cigars, pipes, or cigarettes during the past 6 months.
      • 21. Use of contraindicated medications, including medications with putative disease-modifying properties that do not meet the exposure limits described in Exclusion Criteria #15 and #16, moderate or strong inhibitors of cytochrome P450 (CYP) isozyme 1A2 (CYP1A2) (note ciprofloxacin allowed up to a dose of 500 mg twice daily), and moderate inducers of CYP1A2 (such as tobacco smoke or phenytoin). See Protocol Section 7.5 for complete list.
Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate

Location Details

NCT03221257

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Not yet recruiting

United States, California

University of California Los Angeles

Los Angeles, California, United States, 90095

Not yet recruiting

United States, Colorado

University of Colorado

Aurora, Colorado, United States, 80045

Not yet recruiting

United States, District of Columbia

Georgetown University

Washington, District of Columbia, United States, 20007

Not yet recruiting

United States, Illinois

Northwestern University

Chicago, Illinois, United States, 60611

Not yet recruiting

United States, Indiana

Indiana University Health

Indianapolis, Indiana, United States, 46202

Not yet recruiting

United States, Maryland

Johns Hopkins University

Baltimore, Maryland, United States, 21224

Not yet recruiting

United States, Massachusetts

Harvard Medical School, Brigham & Women's Hospital

Boston, Massachusetts, United States, 02115

Not yet recruiting

United States, Massachusetts

Boston University, School of Medicine

Boston, Massachusetts, United States, 02118

Not yet recruiting

United States, Michigan

University of Michigan

Ann Arbor, Michigan, United States, 48109

Not yet recruiting

United States, New Jersey

Rutgers University

New Brunswick, New Jersey, United States, 08901

Not yet recruiting

United States, New York

Hospital for Special Surgery

New York, New York, United States, 10021

Not yet recruiting

United States, Pennsylvania

University of Pittsburgh

Pittsburgh, Pennsylvania, United States, 15261

Not yet recruiting

United States, South Carolina

Medical University of South Carolina

Charleston, South Carolina, United States, 29425

Not yet recruiting

United States, Texas

University of Texas Medical School at Houston

Houston, Texas, United States, 77030

Not yet recruiting

United States, Utah

University of Utah

Salt Lake City, Utah, United States, 84108

Not yet recruiting

United States, Washington

University of Washington Medical Center

Seattle, Washington, United States, 98195